The rising interest in successful weight management has spurred considerable exploration into groundbreaking treatments. Recently , Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activator , has exhibited encouraging results in clinical trials, suggesting potential for sign